What is it about?

To evaluate the safety and efficacy of cabergoline in men with erectile dysfunction (ED) who did not respond to sildenafil.

Featured Image

Why is it important?

Sildenafil citrate, an orally administered phosphodiesterase-5 (PDE-5) inhibitor generally used to treat erectile dysfunction (ED). It is the first oral medication to exhibit significant and reliable efficacy in most patients with ED.1 Nowadays more than 15 million men have used this medication with primary care specialists writing more than half of these prescriptions


Marketing data worldwide demonstrated that dropout rates for sildenafil are as high as 50% of patients treated. In spite of its effectiveness, yet, approximately 30–50% of subjects receiving sildenafil do not satisfactorily respond to therapy. Proposed rationales for treatment discontinuation include variations in motivation in patients incorporated in the clinical trials and those of the everyday practice, lack of reimbursement, failure to recognize patients expectations from sexual life, lack of a definitive cure, low efficacy, fear of adverse events and need for sexual intercourse scheduling.

Dr Mohammad Reza Safarinejad
University of Medical Sceices

Read the Original

This page is a summary of: Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study, International Journal of Impotence Research, April 2006, Springer Science + Business Media,
DOI: 10.1038/sj.ijir.3901476.
You can read the full text:




The following have contributed to this page